Emboldened by recent R&D successes, Merck KGaA looks at selling off $1B-plus consumer division
Encouraged by two notable drug approvals after a long Siberian winter of failures and setbacks, Merck KGaA has very publicly posted a ‘for sale’ sign in front of its consumer health division.
Backed by a variety of brands, the German Merck says it reaped more than a billion dollars in revenue from the division. But following the OK on the checkpoint cancer drug Bavencio as well as cladribine — its MS laggard now approved in Europe — Merck KGaA is far more whipped up by the potential of its pipeline, looking to drive home a new rep for clinical success which they find far more exciting than the consumer work.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.